Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Year in review: "Best" papers in pediatric pulmonary and sleep medicine in 2025.

Paediatric respiratory reviews·2026
Same author

Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

Rational use of mucoactive medications to treat pediatric airway disease.

Paediatric respiratory reviews·2020
Same author

Five-year follow-up of participants diagnosed with chronic airflow obstruction in a South African Burden of Obstructive Lung Disease (BOLD) survey.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2018
Same author

Evidence-based decision-making for primary care: The interpretation and role of pragmatic trials.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2017
Same author

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).

Clinical and translational allergy·2017
Same journal

Brain-Derived Neurotrophic Factor (BDNF) Signaling in Respiratory Disease: Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications.

Pulmonary pharmacology & therapeutics·2026
Same journal

PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model.

Pulmonary pharmacology & therapeutics·2026
Same journal

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026
Same journal

TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions.

Pulmonary pharmacology & therapeutics·2026
Same journal

Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment.

Pulmonary pharmacology & therapeutics·2026
Same journal

Evodiamine protects against lung ischemia-reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures.

Pulmonary pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System
08:00

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System

Published on: November 17, 2014

Alternative mechanisms for tiotropium.

E D Bateman1, S Rennard, P J Barnes

  • 1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. eric.bateman@uct.ac.za

Pulmonary Pharmacology & Therapeutics
|July 29, 2009
PubMed
Summary
This summary is machine-generated.

Tiotropium effectively treats chronic obstructive pulmonary disease by reducing exacerbations. However, the UPLIFT study found it did not slow lung function decline over four years, despite other clinical benefits.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jun 21, 2026

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System
08:00

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System

Published on: November 17, 2014

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Tiotropium is a common treatment for chronic obstructive pulmonary disease (COPD).
  • While known as a bronchodilator, early studies suggested tiotropium might also slow lung function decline.
  • This prompted further investigation into its mechanisms of action beyond simple bronchodilation.

Purpose of the Study:

  • To examine the hypothesis that tiotropium slows the rate of lung function decline in COPD patients.
  • To summarize existing data on the mechanisms of action for tiotropium's therapeutic effects.

Main Methods:

  • Analysis of data from the UPLIFT study, a four-year investigation into tiotropium's effects.
  • Review of various investigations exploring the basic and clinical research on tiotropium's mechanisms.

Main Results:

  • The UPLIFT study confirmed spirometric and clinical benefits of tiotropium treatment over four years.
  • However, the study did not demonstrate a reduction in the rate of lung function decline with tiotropium addition.
  • Existing research provides insights into potential mechanisms beyond bronchodilation.

Conclusions:

  • Tiotropium provides significant clinical benefits in COPD management, including exacerbation reduction.
  • The drug does not appear to alter the underlying rate of lung function decline in COPD.
  • Further research is needed to fully elucidate tiotropium's multifaceted mechanisms of action.